Literature DB >> 34583518

PROTAC cell permeability and oral bioavailability: a journey into uncharted territory.

Vasanthanathan Poongavanam1, Jan Kihlberg1.   

Abstract

Entities:  

Keywords:  ADME/Tox; drug design; in vitro assays; molecular chameleon; oral druggable space

Mesh：

Substances：

Year:  2021        PMID： 34583518     DOI： 10.4155/fmc-2021-0208

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  5 in total

Review 1.  PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.

Authors:  Jyotsana Madan; Vijay Kamal Ahuja; Kamal Dua; Susanta Samajdar; Murali Ramchandra; Sanjeev Giri
Journal:  BioDrugs       Date:  2022-09-13       Impact factor: 7.744

Review 2.  Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.

Authors:  Sinan Ma; Jianai Ji; Yuanyuan Tong; Yuxuan Zhu; Junwei Dou; Xian Zhang; Shicheng Xu; Tianbao Zhu; Xiaoli Xu; Qidong You; Zhengyu Jiang
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

Review 3.  The current state of the art and future trends in RAS-targeted cancer therapies.

Authors:  Salman R Punekar; Vamsidhar Velcheti; Benjamin G Neel; Kwok-Kin Wong
Journal:  Nat Rev Clin Oncol       Date:  2022-08-26       Impact factor: 65.011

4.  Linker-Dependent Folding Rationalizes PROTAC Cell Permeability.

Authors:  Vasanthanathan Poongavanam; Yoseph Atilaw; Stephan Siegel; Anja Giese; Lutz Lehmann; Daniel Meibom; Mate Erdelyi; Jan Kihlberg
Journal:  J Med Chem       Date:  2022-09-28       Impact factor: 8.039

Review 5.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.